Financial Survey: Catalent (CTLT) and Its Peers
Catalent (NYSE: CTLT) is one of 101 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Catalent to related companies based on the strength of its profitability, earnings, analyst recommendations, institutional ownership, valuation, risk and dividends.
Valuation & Earnings
This table compares Catalent and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Catalent||$2.08 billion||$109.80 million||48.15|
|Catalent Competitors||$8.17 billion||$1.09 billion||157.29|
Catalent’s competitors have higher revenue and earnings than Catalent. Catalent is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
99.4% of Catalent shares are held by institutional investors. Comparatively, 44.5% of shares of all “Pharmaceuticals” companies are held by institutional investors. 1.7% of Catalent shares are held by insiders. Comparatively, 11.3% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
This table compares Catalent and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
This is a summary of current recommendations and price targets for Catalent and its competitors, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Catalent presently has a consensus target price of $44.00, suggesting a potential upside of 6.25%. As a group, “Pharmaceuticals” companies have a potential upside of 18.00%. Given Catalent’s competitors higher possible upside, analysts plainly believe Catalent has less favorable growth aspects than its competitors.
Risk & Volatility
Catalent has a beta of 1.41, meaning that its share price is 41% more volatile than the S&P 500. Comparatively, Catalent’s competitors have a beta of 37.77, meaning that their average share price is 3,677% more volatile than the S&P 500.
Catalent competitors beat Catalent on 7 of the 13 factors compared.
Catalent Company Profile
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products. Its segments include Softgel Technologies, Drug Delivery Solutions and Clinical Supply Services. The Softgel Technologies segment is engaged in the formulation, development and manufacturing of prescription and consumer health soft capsules or softgels. The Drug Delivery Solutions segment is engaged in the formulation, development and manufacturing of prescription and consumer and animal health products; blow-fill seal unit dose manufacturing; biologic cell line development; analytical and bioanalytical development, and testing services. The Clinical Supply Services segment is engaged in manufacturing, packaging, labeling, storage, distribution and inventory management for clinical trials of drugs and biologics for patient kits; FastChain clinical supply service; clinical e-solutions and informatics, and global comparator sourcing services.
Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with Analyst Ratings Network's FREE daily email newsletter.